Introduction {#S1}
============

Although 12% of all human cancers are now known to be caused by viruses([@R45]; [@R62]), the mere presence of viral DNA in a tumor does not necessarily indicate causality. Multiple lines of evidence suggest a viral etiology for cutaneous squamous cell carcinoma (cuSCC). In immunosuppressed solid organ transplant recipients (OTRs), the incidence of cuSCC is 65- to 250-fold higher than in the general population([@R27]; [@R34]; [@R41]); incidence ratios of this magnitude are commonly seen in other viral cancers, including human herpesvirus-8-mediated Kaposi's sarcoma and HBV-associated hepatocellular carcinoma([@R56]). A second line of evidence supporting viral etiology is the behavior of the keratoacanthoma (KA) subtype of cuSCC. KA can spontaneously regress, and has been suggested to lie along a spectrum of carcinogenesis between hyperplastic viral verrucae and neoplastic SCC([@R39]).

Previous studies have selectively focused on human papillomavirus (HPV) as a potential etiologic agent in cuSCC. Investigators have hypothesized an analogy between cuSCC and cervical SCC, as the latter has been firmly associated with high-risk α-genus HPV (α-HPV) infection, including HPV 16 and 18([@R10]; [@R32]). However, different HPV types have site-specific tropism for mucosal or cutaneous epithelium; the high-risk mucosal α-HPV are not found in cuSCC, with the exception of genital and periungual tumors([@R1]; [@R18]; [@R44]). Thus, many studies focus on detection of the cutaneous β-genus HPV types (β-HPV) in cuSCC([@R4]; [@R7]; [@R24]; [@R29]; [@R50]; [@R51]; [@R54]).

The association of β-HPV with cuSCC is clearly defined for a specific group of patients with epidermodysplasia verruciformis, an autosomal recessive genodermatosis associated with susceptibility to β-HPV. Patients with epidermodysplasia verruciformis develop widespread viral warts and β-HPV 5- and 8-mediated SCC([@R28]). However, the β-HPV types have not been firmly associated with cuSCC in the general population([@R32]). β-HPV DNA is detected in 27--54% of SCCs from immunocompetent patients and 55--84% of SCCs from immunosuppressed patients([@R4]; [@R7]; [@R8]; [@R21]; [@R23]; [@R29]; [@R50]; [@R51]). Indeed, in other studies β-HPV has been detected with comparable frequency in normal skin, eyebrow hairs, and premalignant actinic keratoses([@R3]; [@R4]; [@R12]; [@R16]; [@R17]; [@R24]; [@R30]). Other studies have reported an association between antibody responses to β-HPV and the development of cuSCC, particularly for patients with antibodies to multiple HPV types([@R11]; [@R35]).

High-risk α-HPV, which are present in over 95% of cervical SCC, often integrate into the human genome and express viral proteins that interfere with normal cell cycle control (reviewed in([@R9]; [@R61])). The E6 and E7 proteins of the high-risk α-HPV types interfere with the tumor-suppressor activities of cellular p53 and pRB to drive carcinogenesis([@R19]; [@R48]; [@R59]). Ongoing expression of E6 and E7 is required for both induction and maintenance of carcinogenesis. By analogy, β-HPV would be expected to utilize the same mechanism of carcinogenesis, but studies using *in situ* hybridization or RT-PCR to detect HPV mRNA in cuSCC have detected viral transcripts only sporadically and at low levels in occasional tumors, with many other tumors testing negative. ([@R15]; [@R46]). Nevertheless, many authors continue to point to β-HPV as a possible etiologic agent in these tumors.

The goal of our study was to assess whether β-HPV is capable of causing cuSCC through expression of viral oncogenes, using ultra-high throughput sequencing of the SCC transcriptome. This comprehensive, unbiased analysis of total tumor mRNA expression revealed no HPV transcriptional activity, an observation that was further supported by the absence of a substantial viral load in the tumors. These two observations contradict the hypothesis that transcription of viral oncogenes is required for tumor maintenance.

Results {#S2}
=======

Patient Characteristics {#S3}
-----------------------

We enrolled 38 patients, including 27 males and 11 females, ranging in age from 41 to 95 years ([Table 1](#T1){ref-type="table"}). Seventeen patients were immunocompetent and 21 were immunosuppressed due to solid organ transplantation, hematologic malignancy, HIV, or medication for Wegener's granulomatosis. Eighty-nine tissue samples were collected from these patients, including 71 SCCs (23 KA subtype) and 18 normal skin samples. Four tumor samples did not yield enough tissue for DNA extraction but RNA was obtained for transcriptome analysis. Two α-HPV16-mediated primary tumors were obtained for comparison: a periungual SCC from a 53-year-old immunocompetent man, and a stage I nonkeratinizing cervical SCC from a 35-year-old woman. The α-HPV18-mediated HeLa cervical cancer cell line was used as an additional control.

Low Viral Load of β-HPV in Normal Skin and Cutaneous SCC {#S4}
--------------------------------------------------------

Eighty-five DNA samples were assayed for the presence of β-globin DNA by PCR and all demonstrated sufficient quantity and integrity for β-HPV typing. Twenty of 67 cuSCC tumors (30%) were positive for HPV DNA by PCR, 18 of which were confirmed by sequencing. Five of 18 normal skin samples (28%) were also HPV-positive by PCR and sequence confirmation ([Table 2](#T2){ref-type="table"}). Eleven HPV types and 14 incompletely sequenced fragment types were detected, with no single type predominating. Multivariate regression modeling demonstrated no difference in β-HPV carriage between tumor and normal tissue when controlling for age, sex, and immunosuppression as well as clustering for multiple samples from the same patient (p=0.693). Immunosuppression and older age were significantly associated with β-HPV carriage (p=0.018 for both). PCR and sequencing confirmed the presence of α-HPV16 in the primary cervical and periungual SCC and α-HPV18 in HeLa cells. In addition, the periungual SCC was found to contain β-HPV8 and FA51.2 DNA.

Viral loads were determined for up to 3 HPV types in 24 of the 25 HPV PCR-positive and sequence confirmed samples. Replicate assays were performed for HPV18 in the HeLa cervical cancer cell line, HPV16 in the cervical SCC, and HPV16 and HPV8 in the periungual SCC ([Table 2](#T2){ref-type="table"}, [Figure 1A](#F1){ref-type="fig"}). With the exception of 4 samples (1 normal skin and 3 tumors), all viral loads were below 1 HPV copy per cell. In contrast, the cervical SCC contained 2.4 HPV16 copies per cell and the HeLa cell line contained 6.3 copies per cell, consistent with viral integration. The periungual SCC contained 46.9 α-HPV16 copies per cell but only 0.3 β-HPV8 copies per cell.

Random-effects interval regression modeling demonstrated no difference in β-HPV viral load between tumor and normal tissue when controlling for age, sex, and immunosuppression as well as clustering for multiple samples from the same patient (p=0.310). Immunosuppression and age were significantly associated with higher viral load (p=0.016 for immunosuppression; p=0.0004 for age).

No HPV Transcripts Observed in Cutaneous SCC {#S5}
--------------------------------------------

The potential oncogenicity of HPV viruses in our samples was assessed in terms of viral gene expression by mRNA-transcriptome sequencing (mRNA-seq). Thirty-one cuSCC tumors (10 KA type) were assayed by high-throughput mRNA-seq, including 10 β-HPV DNA positive samples with viral loads ranging from undetectable to 13.7 copies per cell. Parallel libraries were prepared from 8 patient-paired normal skin samples as well as the aforementioned periungual SCC tumor, cervical SCC, and HeLa cell samples. Paired-end read counts per library ranged from 1.5 million to 10.6 million reads (corresponding to sequence from 740,000 to 5.3 million cDNA amplicons), with a median count of 3.5 million reads (1.8 million amplicons; [Table S2](#SD1){ref-type="supplementary-material"}). After removing sequences with low sequence complexity or with high quality matches to the human genome or transcriptome, reads were queried against a database of all fully sequenced viral genomes from RefSeq (see Methods). Abundant HPV-matching reads were detected in the HeLa cell-derived and cervical SCC-derived datasets (0.15% and 0.02% of the total reads, respectively [Figure 1B](#F1){ref-type="fig"}). In both, the HPV subtype identified was an α-HPV subtype known to drive tumorigenesis in that sample type (HPV18 and HPV16, respectively)([@R10]; [@R32]). Read frequencies from 2 technical replicate libraries prepared from cervical SCC were nearly identical (0.022% and 0.018%; [Figure 1C](#F1){ref-type="fig"}, [Table S1](#SD1){ref-type="supplementary-material"}).

Abundant HPV16 reads were also detected in the transcriptome of the periungual SCC (0.06% of total reads; [Figure 1B](#F1){ref-type="fig"}), with no reads mapping preferentially to HPV8 or any other HPV subtype. No potentially HPV-derived reads were detected in 30 of the cuSCC tumors and 7 of the paired normal skin samples ([Figure 1B](#F1){ref-type="fig"}). One normal skin sample that was HPV-negative by genomic PCR contained 2 HPV-matching reads (0.00008% of the total reads), and 1 skin SCC sample contained 5 HPV-derived reads (0.0001% of the total read set; this sample had no DNA for genomic PCR).

No libraries contained a higher frequency of total viral-matching reads than the lowest HPV-derived read count amongst the HPV-positive control samples (0.018%), and only 5 had viral read frequencies within an order of magnitude of that value ([File S2](#SD1){ref-type="supplementary-material"}). These 5 samples detected a mixture of phage sequence (likely deriving from bacteria on the skin), human klassevirus 1 (a candidate etiological agent for diarrhea that was isolated from human stool in our lab and is therefore a likely cross-lab contaminant([@R26]); and Moloney murine leukemia virus (MMLV). A reverse transcriptase deriving from the latter was used for library construction (see Methods), making it a likely reagent contaminant. Although MMLV and related viruses do have oncogenic capabilities ([@R14]), the sample in which it was detected at the highest frequency was a normal skin control, not a tumor (sampleID STA01-122, dataset C, barcode CGT, [Table S2](#SD1){ref-type="supplementary-material"} and [File S2](#SD1){ref-type="supplementary-material"}).

In these 39 cases of normal skin and cuSCC, the frequencies of HPV reads were orders of magnitude less than those observed for any of the bona fide HPV-driven tumors. In control samples for which both mRNA-seq and viral genome load data were obtained, the results obtained by these 2 metrics agreed with one another and with prior descriptions of the role of HPV as an oncogenic virus; genomes and transcripts were both abundant in HeLa cells and cervical SCC and both absent in healthy skin ([Figure 1C](#F1){ref-type="fig"}). The similarity of HPV genome and transcriptome quantitation between HeLa cells and cervical SCC versus periungual SCC supported the role for HPV in periungual SCC tumorigenesis, while the quantitative similarity between the cuSCC versus healthy skin samples implied no role for HPV transcription in the maintenance of those tumors.

Discussion {#S6}
==========

Previous studies have proposed β-HPV as a potential causative agent in cuSCC, citing the presence of viral DNA in tumor tissue, but these have not definitively proved an epidemiologic association or evaluated any particular mechanism of transformation. We used whole transcriptome sequencing to test the hypothesis that HPV is required for the maintenance of cuSCC through expression of viral oncoproteins. Transcriptome sequencing revealed a complete absence of HPV mRNA in these tumors, similar to paired normal skin. This stood in stark contrast to the abundant HPV messages detected in cervical SCC and its derivative HeLa cell line. Our results in fact, contradict the hypothesis that expression of viral oncogenes is required for maintenance of cuSCC.

Periungual SCC represents a special site on the cutaneous epithelium. These tumors are associated with high-risk α-HPV([@R1]; [@R37]; [@R44]), which has been reported as episomal, and in a single case, integrated([@R47]; [@R55]). In our control periungual SCC, β-HPV8 and FA51.2 DNA were detected along with α-HPV16. This tumor contained 46.9 α-HPV16 copies per cell but only 0.3 β-HPV8 copies per cell. HPV16 mRNA reads represented 0.06% of the transcriptome, but no β-HPV mRNA reads were detected. Taken together, this control specimen supports our impression of α-HPV as the driver and β-HPV as a mere passenger in periungual SCC.

As in previous studies([@R3]; [@R4]; [@R7]; [@R8]; [@R12]; [@R16]; [@R17]; [@R21]; [@R23]; [@R24]; [@R29]; [@R30]; [@R50]; [@R51]), β-HPV DNA was detectable by nested PCR in 30% of SCC, but was also found in a comparable proportion (28%) of normal skin samples. Moreover, we found extremely low viral loads in tumors that were positive for the viral genome. In all but 3 tumor samples, the viral load was less than 1 copy per cell. Importantly, the 3 contradictory samples all came from a single renal transplant recipient with multiple KAs of the lower leg and may reflect a unique feature of that case. Use of PCR and sequencing allowed identification of a broad range of HPV types although the multiplicity of infection may be limited by the number of clones sequenced. Alternate methods for β-HPV detection such as line blots and microarrays allow simultaneous detection of types but are limited in the types detected. While DNA from other HPV types may be present in these samples, this does not alter the conclusion of this study. The low copy number of β-HPV DNA, combined with the absence of virally-derived oncogenic messages, strongly suggest that β-HPV transcription is not required for tumor maintenance.

Our data were consistent with previous evidence that β-HPV merely colonizes the skin. Immunosuppression and older age were associated with a higher prevalence and viral load of β-HPV, consistent with prior studies([@R13]; [@R17]; [@R53]). These phenomena likely reflected the role of the immune system and age-related immune senescence in controlling epidermal colonization with HPV rather than explaining the increased incidence of SCC in OTRs and older patients. The prevalence of HPV DNA in tape-stripped biopsies is far lower than that on the surface, further supporting a passenger role([@R22]). Support for β-HPV as a passenger also comes from a study of tumors from patients with xeroderma pigmentosum, in which prevalence of viral carriage increases with age and is very low in tumors from children([@R42]). A reversed relationship in which SCC somehow results in the presence or increase of β-HPV DNA or antibodies is possible, although further investigation would be required to substantiate this.

Insertional mutagenesis is another mechanism of viral oncogenesis; this mechanism has been described for oncoretroviruses but not for DNA viruses. High-risk α-HPV types can integrate into the host genome but require continual expression of the viral E6 and E7 proteins for their oncogenic activities([@R19]; [@R48]; [@R59]). The recently described Merkel cell polyomavirus (MCV), another small DNA oncovirus, also integrates into the host genome([@R20]), but continued expression of the MCV truncated large T antigen is similarly required for carcinogenesis([@R31]). In contrast, there are no reports of β-HPV integration into the genome of cuSCC. The low viral loads of β-HPV in cuSCC reported here further indicate that, even if β-HPV had integrated, only at most only a small proportion of the genomes within any tumor could contain integrated β-HPV, casting doubt upon integration as a carcinogenic mechanism.

It has also been suggested that β-HPV might play a role in induction but not maintenance of cuSCC (based on higher viral load of HPV in precancerous actinic keratoses versus primary SCC, metastatic tumor, or perilesional skin([@R57])). This may occur by interfering with cellular DNA repair or apoptosis following UV-irradiation, creating a pool of genomically unstable cells at risk of oncogenic transformation. Our study was not designed to address this hypothesis. But it should be noted that such a hypothesis would represent a substantial departure from the role played by α-HPV in mucosal SCC, and from the carcinogenic mechanisms known to be employed by other families of DNA tumor viruses in general. Therefore, the most straightforward interpretation of our data is that the sporadic and low-level presence of β-HPV genomic DNA in these tumors, unaccompanied by evidence of active viral gene expression, most likely represents colonization rather than an etiologic association.

Materials and Methods {#S7}
=====================

Sample Collection {#S8}
-----------------

All subjects provided informed consent according to procedures approved by the University of California, San Francisco Committee on Human Research and adherent to the Helsinki Guidelines. Tumor tissue was collected from patients during the course of biopsy or excision. All specimens were held for further processing until final pathology confirmed a diagnosis of cuSCC. Normal tissue was collected when surgical discard was available from postoperative reconstruction. All tissue was snap-frozen and stored on liquid nitrogen until nucleic acid extraction.

A primary cervical cancer specimen containing HPV16 was obtained from a commercial tissue bank (ILSBio, LLC, Chestertown, MD).

Nucleic Acid Isolation {#S9}
----------------------

Tissue samples were minced, divided, and placed in parallel extraction pathways. DNA was extracted using the QIAamp DNA Mini Kit with RNase A (Qiagen, Valencia, CA) as per manufacturer's protocol. RNA extractions were carried out using the RNeasy Lipid Tissue Mini Kit with on-column RNase-free DNase I (Qiagen) as per manufacturer's protocol.

Human Papillomavirus DNA Detection using PCR {#S10}
--------------------------------------------

A PCR assay for β-globin DNA was performed on each sample to control for DNA integrity and for the presence of adequate quantity of DNA. Five μL of each DNA sample (30--800ng) were tested with primers PCO4 and GH20 as described([@R5]). β-HPV PCR was carried out using the nested primer sets FAP59-FAP64 and FAP6085F-FAP6319R ([@R23]; [@R24]). For the first round of PCR, 5 μL of each DNA sample were amplified using 2μM of the FAP59 and FAP64 primers in a 50μL reaction volume including 1× Taq Buffer, 2mM MgCl2, 0.25mM dNTPs, and 1U Taq polymerase. The reaction was carried out under the following PCR conditions: 94° for 2 minutes followed by 25 cycles of 94° for 30 seconds, 50° for 1 minute, and 72° for 1 minute, with a final extension time of 7 minutes at 72°. A 5μL aliquot of the product was removed for a second round of amplification using the nested FAP 6085F and FAP 6319R primer pair under the same cycling conditions. α-HPV PCR was carried out using the nested primer sets MY09-MY11 and GP5-GP6 as described([@R43]; [@R52]).

The products were visualized by agarose gel electrophoresis and bands of expected size were isolated using the PureLink Quick Gel Extraction Kit (Invitrogen, Carlsbad, CA) and cloned using the TOPO TA cloning System (Invitrogen). A minimum of 12 colonies were sequenced on the ABI 3130xl Genetic Analyzer (Applied Biosystems, Carlsbad, CA) in order to detect potential multiple infections.

Quantification of HPV Viral Load by Real-time qPCR {#S11}
--------------------------------------------------

Quantitative real-time PCR was performed using the Universal Probe Library (UPL) system (Roche Applied Science, Indianapolis, IN). Primer and probe assay combinations were individually designed for each HPV type and for human β-2-microglobulin (B2M) using the online UPL Design Center software (Roche). For samples with multiple infections, we designed discriminatory assays to measure type-specific viral loads of as many individual types as possible ([Table S1](#SD1){ref-type="supplementary-material"}). To generate standard curves, assay-specific PCR amplicons were separated on 4% agarose gel and purified using the PureLink Quick Gel Extraction Kit (Invitrogen). Internal standards were generated using 10-fold dilutions of the gel-purified products ranging from 1,000,000 to 10 input copies.

DNA samples were assayed in 20μL reactions with a final concentration of 1× LightCycler 480 Probes Master mix, 400nM of each primer, and 200nM of the UPL probe. Using the LightCycler 480 (Roche), samples were heated to 95° for 10 minutes followed by 45 cycles of 95° for 10 seconds, 60° for 30 seconds, and 70° for one second. Data was analyzed with the LightCycler 480 software. DNA samples and standard dilution series were run in duplicate, and total input copy numbers were calculated using the mean crossing point (Cp) values for each sample. Input cellular equivalents were calculated based on 2 copies of β2M copies per cell, and HPV viral loads were calculated as viral copies per cell.

Statistical Analysis {#S12}
--------------------

HPV prevalence was analyzed by logistic regression including age, sex, immunosuppression, tissue sample type, and accounting for clustering of multiple samples within patients. HPV viral loads were analyzed with random-effects interval regression where the HPV copy number was left-censored at the lower limit of detection by qPCR. For both prevalence and viral load, univariate regression was performed prior to multivariate modeling. Statistical analysis was performed using Stata 11 (StataCorp LP, College Station, TX).

mRNA-seq Library Preparation and Analysis {#S13}
-----------------------------------------

Poly(A)+ RNA was isolated from 3 μg of total RNA using the Oligotex Mini kit (Qiagen) according to manufacturer's instructions. The resulting poly(A) RNA was then amplified using the MessageAmp II aRNA Amplification Kit (Ambion, Austin, TX) using an in vitro transcription time of 14 hours at 37°C to generate aRNA. 200ng of aRNA was used to generate libraries for transcriptome sequencing using an adaptation of the protocol previously described by Yozwiak *et al*. (Yozwiak *et al.*). In order to multiplex up to 16 samples within 1 sequencing library, aRNA samples were randomly primed and reverse transcribed using a primer containing a 14-bp sequence common to the 3′ end of both Illumina adapters, a random monomer followed by a unique 3-bp barcode, and a random hexamer (pr1A_barcode). Second-strand synthesis was primed using pr1A followed by PCR amplification using the 18-bp Illumina/barcode sequence without the hexamer (pr1B_barcode) for 25 cycles. PCR products were purified using DNA Clean and Concentrator columns (Zymo Research, Orange, CA). 200ng of each individually barcoded sample were mixed together to generate a library of up to 16 samples, with each sample marked by a unique 3-bp barcode. Library purification, size selection, and amplification proceeded as previously described (Yozwiak *et al.*). Three multiplexed transcriptome libraries were analyzed on 3 separate paired-end sequencing runs using the Genome Analyzer II (Illumina, San Diego, CA) and designated Datasets A, B, and C. Barcodes and corresponding samples are listed in [Table S2](#SD1){ref-type="supplementary-material"}. Each run generated pairs of 65nt reads. This data has been submitted to the NCBI Sequence Read Archive under accession number SRA029929.

Read pairs from each library were sorted by 3nt barcode (nucleotides 2--4 of each read), requiring that at least 1 of the 2 reads from each pair contained a perfect match to an input barcode and that the other contained at most 1 mismatch. This yielded the "total" read counts shown in [Table S2](#SD1){ref-type="supplementary-material"}. For analysis, we removed from each read the nucleotide preceding the barcode, the barcode itself, the 6 nucleotides deriving from the random hexamer used for priming, and the last nucleotide of the read, yielding 54nt reads.

Background model (BGM) DNA sequence datasets included the human genome (UCSC build hg18; BGMhg)([@R25]; [@R38]), the human mRNA transcriptome (Representative H-Invitational transcripts, 43,159 records; BGMht)([@R33]), a collection of sequenced human VDJ recombination products (*H. sapiens* entries from IMGT release 201028-6 67,611 records; BGMvdj)([@R40]), the Illumina paired-end adapter sequences ligated to one another (BGMad), and an *in vitro*-transcribed *Xenopus* EF1α message that contaminated Dataset A and was reconstructed from that data ([File S1](#SD1){ref-type="supplementary-material"}; BGMef1a). Matches to BGMhg, BGMht, and BGMef1a of \>80% sequence identity across the entire read length were sought using BLAT (-minIdentity=80 -noTrimA)([@R36]), and matches to those datasets plus BGMvdj and BGMad were sought using Blastn (default settings)([@R2]). Matching sequences and their paired ends were filtered from the query pool, leaving the "host-filtered" read counts shown in [Table S2](#SD1){ref-type="supplementary-material"}. Barcode AGG from Dataset A was excluded from further analysis due to the majority of reads mapping to the BGMef1a contaminating sequence (not shown). Low-complexity sequences were defined as those generating \<30 new additions to the string table during an LZW compression ([@R58]) and were removed, leaving the "complexity-filtered" read counts shown in [Table S2](#SD1){ref-type="supplementary-material"}.

Matches to the remaining reads were sought in a database of all complete viral genome sequences in Genbank (3525 records; 72 million nucleotides; downloaded on 1/18/2010; GI's listed in [File S3](#SD1){ref-type="supplementary-material"}) ([@R6]) using tBlastx (-e 1e-3). Read counts were allocated to the viral genome record with the highest alignment bitscore. In the case of a tie, the read count was initially distributed evenly to all records with equal bitscore matches, then re-assigned to whichever record(s) had the greatest total read count for the given dataset. "HPV-matching" read counts for each sample are shown in [Table S2](#SD1){ref-type="supplementary-material"}.
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![Comparison of HPV DNA viral load and abundance of HPV-derived transcripts for established HPV-driven cancers versus normal skin and cuSCCs\
(A) HPV DNA viral loads determined by type-specific qPCR. For each sample with multiple type infection, the sum of the type-specific viral loads is shown (for details, see [Table 2](#T2){ref-type="table"}.) (B) Abundance of HPV-derived transcripts determined by mRNA-seq. Reads were filtered to remove host-derived and low-complexity sequence prior to viral mapping (see methods), and HPV counts are each presented as a percentage of their total dataset. The most frequently matched HPV type for the HeLa, periungual SCC, and cervical SCC samples is indicated. Cervical cancer is presented as the union of 2 technical replicate datasets. (C) Congruence between HPV genomic load (blue; presented as in panel A) and abundance of HPV-derived transcripts (red; presented as in panel B) among those control samples from which both types of data were collected.](nihms280295f1){#F1}

###### 

Demographics

                               Total    Male     Female
  ---------------------------- -------- -------- --------
  **Patients**                 38       27       11
   **Immunocompetent**         17       10       7
   **Immunosuppressed**        21       17       4
    Solid Organ Transplant     12       9        3
    Hematologic Malignancy     6        5        1
    HIV                        2        2        0
    Wegener's Granulomatosis   1        1        0
  **Age Range (Years)**        41--95   41--95   52--95

                                Total       Male       Female
  ----------------------------- ----------- ---------- -----------
  **SCC Samples \[KA type\]**   71 \[23\]   45 \[8\]   26 \[15\]
   **Immunocompetent**          30 \[16\]   14 \[6\]   16 \[10\]
   **Immunosuppressed**         41 \[7\]    31 \[2\]   10 \[5\]
    Solid Organ Transplant      28          19         9
    Hematologic Malignancy      10          9          1
    HIV                         2           2          0
    Wegener's Granulomatosis    1           1          0
  **Normal Skin**               18          14         4
   **Immunocompetent**          8           6          2
   **Immunosuppressed**         10          8          2
    Solid Organ Transplant      8           6          2
    Hematologic Malignancy      2           2          0

###### 

HPV Viral Loads.Patients with HPV PCR positive samples shown.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient     Sex   Age   Immunosuppression           Sample\       Histology     Site       DNA HPV Types                  Viral\    Transcriptome\                      
                                                      Code                                                                  Load      Sequenced                           
  ----------- ----- ----- --------------------------- ------------- ------------- ---------- ------------------------------ --------- ---------------- --------- -------- -----
  PC-021      M     89    No                          STA01-046     KA            Scalp      FA7, FA127, FA37               FA7       ND               3921      ND       

                                                                                                                            FA37      ND               3921      ND       

                                                      STA01-051     KA            Scalp      HPV21, FA127, FA37             HPV21     ND               13952     ND       

                                                                                                                            FA37      100              13952     0.007    

                                                      STA01-053     Normal skin   Leg        HPV80, FA7                     HPV80     ND               6434      ND       

                                                                                                                            FA7       28               6434      0.004    

                                                                                                                                                                          

  PC-031      M     95    No                          STA01-130     SCC           Scalp      \-                                                                           

                                                      STA01-131     Normal skin   Scalp      HPV5, HPV8                     HPV5      220872           2313      95.501   

                                                                                                                            HPV8      ND               2313      ND       

                                                                                                                                                                          

  PC-046      M     84    No                          STA01-068     SCC           Hand       HPV75, FA108                   HPV75     149              14607     0.010    

                                                      STA01-079     Normal skin   Leg        HPV75                          HPV75     152              4651      0.033    

                                                                                                                                                                          

  PC-003      M     68    Heart Transplant            STA01-034     SCC           Forehead   HPV5, HPV49, FAIMVS14          HPV5      696              2611      0.267    

                                                      STA01-122     Normal skin   Cheek      \-                                                                           Yes

                                                                                                                                                                          

  PC-015      F     53    Heart-Lung Transplant       STA01-018     SCC           Arm        HPV9                           HPV9      984              28332     0.028    Yes

                                                      STA01-076     Normal skin   Arm        HPV9                           HPV9      57               33490     0.001    Yes

                                                      STA01-077     KA            Arm        HPV9                           HPV9      ND               7264      ND       Yes

                                                      STA01-094     Normal skin   Forehead   \-                                                                           Yes

                                                      STA01-095     SCC           Forehead   \-                                                                           Yes

                                                                                                                                                                          

  PC-007      M     57    Lung Transplant             STA01-074     SCC           Scalp      HPV20, HPV21                   HPV20     1256             51462     0.024    Yes

                                                                                                                            HPV21     10407            51462     0.202    

                                                      STA01-078     Normal skin   Scalp      HPV21, HPV20                   HPV20     ND               47880     ND       

                                                                                                                            HPV21     ND               47880     ND       

                                                                                                                                                                          

  PC-041      M     60    Lung Transplant             STA01-029     SCC           Cheek      HPV17                          HPV17     26132            45136     0.579    

                                                      STA01-030     SCC           Cheek      Sequence Not Obtained                                                        Yes

                                                                                                                                                                          

  PC-058      M     51    Lung Transplant             STA01-010     SCC           Lip        HPV5, HPV80, FA14              HPV5      ND               6693      ND       Yes

                                                                                                                            HPV80     ND               6693      ND       

                                                                                                                            FA14      492              6693      0.074    

                                                      STA01-045     SCC           Cheek      FANIMVS11.4, FAIMVS11.3        NA                                            

                                                      STA01-059     SCC           Cheek      \-                                                                           

                                                      STA01-132     SCC           Scalp      \-                                                                           

                                                      STA01-133     Normal skin   Cheek      \-                                                                           

                                                                                                                                                                          

  PC-030      F     73    Renal Transplant            STA01-031     KA            Leg        FA14, FA16.3                   FA14      28006            5098      5.494    

                                                                                                                            FA16.3    1068             5098      0.209    

                                                      STA01-032     KA            Leg        FA16.3, FA75                   FA16.3    ND               17901     ND       

                                                      STA01-090     KA            Leg        FA14, HPV96, FA140.2, FA16.3   FA14      17216            4712      3.654    

                                                                                                                            FA16.3    ND               4712      ND       

                                                                                                                            FA140.2   ND               4712      ND       

                                                      STA01-091     KA            Leg        FA16.3, FA140.2, FA14          FA14      1808             3372      0.536    Yes

                                                                                                                            FA16.3    44140            3372      13.089   

                                                                                                                            FA140.2   110              3372      0.033    

                                                                                                                                                                          

  PC-054      M     55    Renal/Pancreas Transplant   STA01-065     SCC           Arm        \-                                                                           

                                                      STA01-066     SCC           Arm        HPV8                           HPV8      4462             25593     0.174    Yes

                                                                                                                                                                          

  PC-011      M     64    CLL/SLL                     STA01-064     SCC           Forehead   HPV19, HPV49, FA123            HPV19     1132             26360     0.043    Yes

                                                                                                                            FA123     4717             26360     0.179    

                                                      STA01-071     SCC           Forehead   HPV19, FA33                    HPV19     38               3883      0.010    

                                                                                                                                                                          

  PC-053      M     53    HIV                         STA01-099     SCC           Forehead   HPV5, FA16                     HPV5      1126             32837     0.034    Yes

  PC-043      M     53    No                          STA01-035     SCC           Hand       HPV16                          HPV16     570172           12156     46.904   Yes

                                                                                             HPV8, FA51.2                   HPV8      3685             12157     0.303    Yes

  HeLa        F                                       HeLa          Cell Line     Cervix     HPV18                          HPV18     8496079          1350389   6.291    Yes

  ILS-19363   F     35    No                          ILS-19363-1   SCC           Cervix     HPV16                          HPV16     3403823          1403307   2.426    Yes
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ND: Not detected NA: No assay could be designed SCC: Squamous cell carcinoma KA: Keratoacanthoma MDS: Myelodysplastic syndrome ALL: Acute lymphoblastic leukemia CLL/SLL: Chronic lymphocytic leukemia/Small lymphocytic lymphoma SCT: Stem cell transplant GVHD: Graft vs. host disease.
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